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SUMMARY STATEMENT 
Best Disease is diagnosed in the presence of a well-defined vitelliform shaped macular 
lesion.  We now describe a second, highly recognisable and reproducible retinal 
phenotype associated with a specific BEST1 mutation - p.Ala243Val. 
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The retinal phenotype associated with the p.Ala243Val BEST1 mutation. 
Abstract 
Purpose: 
To describe a highly recognisable and reproducible retinal phenotype associated with a 
specific BEST1 mutation - p.Ala243Val. 
Methods: 
Retrospective review of consecutive cases where genetic testing has identified 
p.Ala243Val BEST1 as the cause of disease.  Electronic patient records were used to 
extract demographic, as well as functional and anatomical data. We then compared 
these data to those observed with the most common BEST1 genotype, p.Arg218Cys.   
Results 
Eight individuals (six families) were identified with the p.Ala243Val BEST1 mutation 
and seven patients with the pathological variant p.Arg218Cys. No patients with 
mutation of codon 243 knowingly had a family history of retinal disease, whereas all 
patients with the p.Arg218Cys variant did. The maculopathy was bilateral in all cases. 
The p.Ala243Val mutation was associated with a pattern dystrophy type appearance, 
most visible with near infra-red reflectance and fundus autofluorescence imaging. This 
phenotype was never observed with any other genotype. This mutation was associated 
with an older median age of symptom onset (median = 42, IQR = 22) compared with 
those harbouring the p.Arg218Cys mutation (median = 18, IQR = 12; Mann Whitney U 
test p<0.05). Despite their older age, the final recorded acuity appeared to better in the 
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p.Ala243Val group (median = 0.55, IQR = 0.6475; median = 0.33, IQR = 0.358) although 
this did not reach statistical significance (Mann Whitney U test p>0.05).  
Conclusions 
 The mutation p.Ala243Val is associated with a highly recognisable and reproducible 
pattern dystrophy-like phenotype. Patients develop symptoms at a later age, and tend to 
have better preservation of EOG amplitudes. 
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The Fundus Phenotype Associated With The p.Ala243Val BEST1 mutation. 
Introduction  
Mutations in the BEST1 gene are a common cause of inherited macular disease.1 In the 
majority of cases heterozygous missense variants in the first half of the gene result in a 
single vitelliform lesion centred on the macula, the classical phenotype associated with 
Best disease (BD, OMIM 153700).2, 3 Most have a family history consistent with 
dominant transmission, although non-penetrant carriers and unilateral presentation 
rarely occur[kk1].4 Less commonly homozygous or compound heterozygous mutations in 
BEST1 result in recessive disease.5 This is usually associated with multifocal subretinal 
deposit, intraretinal and subretinal fluid accumulation even in the absence of choroidal 
neovascular membrane, short axial length and narrow irido-corneal angles.6 In addition, 
much rarer phenotypes also have been described (microcornea, rod-cone dystrophy, 
cataract and posterior staphyloma, autosomal dominant vitreo-retino-choroidopathy 
(both OMIM 193220) and retinitis pigmentosa (OMIM 613194).7, 8 In addition to causing 
BD, a maculopathy usually evident in childhood, mutation of BEST1 can also produce a 
similar appearance later in life, often after the fourth decade. Adult-onset vitelliform 
macular dystrophy (AVMD, OMIM 608161) is genetically heterogeneous with 
pathogenic variants in PRPH2, IMPG1 and IMPG2 as well as BEST1 associated with this 
phenotype.9 Perhaps the least well-recognised presentation of BEST1 related 
retinopathy is a form that mimics the reticular type of pattern dystrophy (PD).10-12 Here 
we present a detailed investigation of a subset of patients presenting with a pattern 
dystrophy, all found to result from the p.Ala243Val BEST1 mutation.   
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Methods 
Patient 4 (see Table 1) presented to the eye clinic at Moorfields Eye Hospital, London 
and was diagnosed with a macular dystrophy after clinical and electrophysiological 
examinations.  Molecular genetic testing identified p.Ala243Val BEST1 as the causative 
variant. As the presentation was not typical for BD, we chose to further investigate the 
phenotype associated with this specific mutation, interrogating an in-house database to 
identify all patients harbouring this variant. The clinical findings were then compared to 
those seen with the most prevalent BEST1 mutation, p.Arg218Cys, chosen to serve as an 
example of “classical” BD. Finally, the phenotype associated with all other BEST1 
variants in our database were reviewed for comparison. 
Clinical details and patient demographics were reviewed using the patients’ hospital 
notes and electronic patient records (OpenEyes, London, UK). Fundus images included 
optical coherence tomography (OCT) with accompanying near infrared reflectance 
imaging (NIR-R) and fundus autofluorescence (FAF), both acquired using the Spectralis 
HRA and OCT system (Heidelberg Engineering, Heidelberg, Germany). 
Electrophysiological testing was performed incorporating the International Society of 
Clinical Electrophysiology of Vision standards and included full field electroretinogram 
(ERG), pattern electroretinogram (PERG) and electro-oculogram (EOG).13, 14 Molecular 
testing was performed either by Sanger sequencing (National Genetics Reference 
Laboratory (NGRL), Manchester, UK) or targeted Next Generation Sequencing of genes 
known to cause macular dystrophy (Macular panel, Casey Eye Institute, Portland, 
Oregon, USA). All patients had previously provided informed consent as part of a 
genetics research project approved by the local research ethics committee, and all 
investigations were conducted in accordance with the principles of the Declaration of 
 8 
Helsinki. The data was analysed using non-parametric statistical methods (Mann 
Whitney U test) and presented as median plus interquartile range (IQR). Significance 
was reported testing at the 5% level.  
Results   
Eight individuals (six families) were identified with the p.Ala243Val BEST1 mutation 
and seven patients with the pathological variant p.Arg218Cys (Table 1). No patients 
with mutation of codon 243 knowingly had a family history of retinal disease, however 
a family survey in two pedigrees identified one further asymptomatic individual 
(patients 1a and 2a). Patients carrying the p.Arg218Cys variant could all identify at least 
one other affected family member. Patients presented with bilateral disease in all cases, 
independent of their genotype. The p.Ala243Val mutation was associated with an older 
median age of symptom onset (median = 42, IQR = 22) compared with those harbouring 
the p.Arg218Cys mutation (median = 18, IQR = 12; Mann Whitney U test p<0.05; see 
Table 1). Despite their older age, the final recorded acuity appeared to better in the 
p.Ala243Val group (median = 0.55, IQR = 0.6475; median = 0.33, IQR = 0.358) although 
this did not reach statistical significance (Mann Whitney U test p>0.05). 
Fundus examination identified classical changes associated with BD in all patients with 
mutation of codon 218 – representative of the various stages of disease (Figure 1A). 
This was confirmed by retinal imaging (SD-OCT and FAF, Figure 1B, C). However, 
patients with the p.Ala243Val mutation did not always share this typical appearance. A 
single macular lesion was usually identifiable on fundoscopy, especially early in the 
disease course (patient 1, Figure 2A). Later, peripheral spokes may have developed, in a 
pattern dystrophy-like appearance (Figure 2B).  
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SD-OCT scans confirmed the presence of subretinal fluid (SRF), a hallmark of BEST1-
related retinopathy. In addition, small amounts of subretinal deposit were seen to 
collect preferentially in the periphery of the elevated neurosensory retina, either in a 
continuous ring of peripheral deposit (Figure 3A), or as radiating spokes (Figure 3B). 
This material was highly reflective when viewed with NIR-R imaging and most easily 
visible with this modality (Figure 4A, 4B). In some cases these changes extended into 
the peripheral macula  (Figures 4C). Areas of outer retinal thickening, particularly in the 
superior retina involving the interdigitating zone were also noted. A similar pattern of 
change was identifiable on FAF, although less clearly defined (Figure 5A, 5B). Subretinal 
deposit was associated with hyperautofluorescence, and in some cases a deposit: fluid 
interface was seen. Again with this modality, the main lesion in most cases did not 
conform to an approximately circular shape, and often had radial spoke-like extensions. 
Similar OCT or FAF changes were not observed with the allele p.Arg218Cys.  
Electrophysiological testing was available for review in 7/8 cases associated with BEST1 
p.Ala243Val. The ffERG was normal in all cases, whilst the EOG and PERG were 
abnormal in all but one patient who had a normal EOG (Patient 5). The median Arden 
ratio was 130% (IQR 24). The absence of a light rise in two cases (Patients 3 and 4) 
directed genetic screening towards BEST1. In contrast the p.Arg218Cys mutation was 
always associated with a reduced Arden ratio in the 4/7 cases tested, with a median 
amplitude of 117.5% (IQR 10). These data suggest that this specific mutation of codon 
243 may have less impact on the amplitude of the EOG light rise than the p.Arg218Cys 
variant (Mann Whitney U test p<0.05). 
In an attempt to discover whether this specific phenotype is seen in the context of other 
BEST1 genotypes we then reviewed the retinal images of other patients, identified from 
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an in-house database, known to have molecularly proven BD. The retinal appearance 
resulting from p.Ala243Val BEST1 was not reproduced by more than 20 further 
genotypes. 
Discussion 
In this work we describe a highly recognisable and reproducible retinal phenotype 
associated with a specific BEST1 mutation - p.Ala243Val. The unique anatomical 
changes are best identified with NIR-R imaging, in addition to SD-OCT and FAF. This 
variant appears milder than others causes of BD, as patients develop symptoms at a 
later age, and tend to have better preservation of EOG amplitudes. These data will be 
invaluable both clinically, aiding the diagnosis of new cases, and scientifically, when 
attempting to better understand this protein’s function. 
So far over 200 mutations in BEST1 have been described, most of which are 
heterozygous and associated with a vitelliform macular dystrophy (http://www-
huge.uni-regensburg.de/BEST1_database). BD in its classical form is a childhood-onset 
condition characterised by the accumulation of subretinal deposit centred on the fovea.4 
Causative genetic variants almost exclusively occur in the highly conserved amino 
terminal domain of BEST1 (amino-acids 1-390) and it is thought that missense 
mutations causing BD act by exerting a dominant negative effect, altering calcium 
sensitive chloride conductance through this channel.15 BEST1 haploinsufficiency, as 
occurs in carriers of recessive BEST1 disease, is not associated with any detectable 
retinopathy. The phenotype arising from the p.Ala243Val mutation is milder than 
classical BD, with a later age of visual loss and absence of a large volume of central 
deposit.  
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 The substitution p.Ala243Val has been previously identified as a cause of BD, AVMD 
and in one report PD. Kramer et al describe three pedigrees with BD and five with 
AVMD arising from mutation of codon 243.16 Unusually the patients with BD were older 
than expected (most were symptomatic after the age of 30) and the sole paediatric 
patient aged 15 showed only the earliest signs of disease (described by the authors as 
pre-vitelliform stage). Although clinical images are not available, the description is that 
of a milder disease than is usual for BD. BD has also been reported once before with the 
same genotype, by Chung et al. in 2001.17 This patient was seen aged 23 with a 
unilateral gliotic macular scar presumed to result from prior choroidal 
neovascularisation. There was no comment on the fellow eye. The same mutation was 
reported by Querques et al. in 2009 where they describe five members of a single 
family.18 No fundus images are available for review. The youngest mutation carriers 
(aged 13 and 17) had not yet developed a visible phenotype, again perhaps suggesting a 
disorder with a later onset. Lastly, and in the only case where fundus images were 
published, Boon et al. describe a patient with a pattern dystrophy-type maculopathy 
due to the p.Ala243Val mutation.19 In this case, and most of the cases herein, the Arden 
ratio was found to be larger than that usually associated with BD. The clinical evidence 
presented therefore supports a role for this variant having a milder effect than most 
heterozygous mutations in BEST1. 
The BEST1 gene encodes a channel protein that selectively transports anions and 
localises to the basolateral RPE cell membrane.20-23 Recently however an alternative 
location has been suggested. Singh et al. generated mutant RPE cells using induced 
pluripotent stem cells derived from fibroblasts of patients with BD.24 They propose that 
the channel is sited in the RPE cytosol, near to but not actually in the basolateral 
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membrane, probably residing in the endoplasmic reticulum (ER). Whilst its preference 
is for chloride ions the channel may additionally transport other monovalent anions 
(bromine, iodine, thyocynate, bicarbonate and nitrate) and even glutamate and GABA.25 
In the ER it is thought to have a role in calcium homeostasis. Yu et al. investigated the 
functional consequences of the p.Ala243Val variant in patch clamping studies, 
overexpressing the mutated BEST1 protein in HEK293 cells.26 The currents detected 
were approximately 10% as large as those measured through wild-type channels.26 
They, and others, were also able to show that p.Ala243Val BEST1 is expressed on the 
cell surface at approximately the same level as wild-type BEST1, suggesting that this 
missense mutation reduces ion conductance through the channel rather than 
mislocalising the channel.26 27, 28 These data are also in keeping with a hypothesis where 
the effects of mutation are to alter normal function. A more dramatic change in function, 
perhaps even a reversal of polarity, may be associated with mutation of key pore 
forming residues.29  
 
Whilst it is easy to understand what consititutes a milder form of disease, one with a 
later onset and less pronounced maculopathy, it is not intuitive how this is brought 
about at a molecular level. A major difference between the PD and vitelliform 
phenotypes is the reduced quantity of subretinal deposit in the former, as well as an 
altered distribution. The accumulating material in classical BD is usually highly 
autofluorescent, and derives from undigested photoreceptor outer segments loaded 
with bisretinoid product that are thought to accumulate due to impaired phagocytosis. 
A similar phenotype occurs with mutation of PRPH2, where mutated photoreceptor 
outer segments are either shed in greater numbers or are more resistant to RPE 
phagocytosis.9 Lastly, mutation of IMPG1 and IMPG2 can also generate a vitelliform 
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maculopathy, and again it is suggested that impaired clearance of outer segments is the 
cause.30 Here the p.Ala243Val mutation is associated with significant amounts of 
subretinal fluid, even in the earliest stages of disease. It may well be that detachment of 
the neurosensory retina is the primary event, and photoreceptor outer segments 
accumulate as a consequence, in a manner not dissimilar to that observed with another 
retinal disease - central serous chorioretinopathy. This mutation may therefore impair a 
specific aspect of RPE function, uniquely altering ion flux and the associated osmotic 
movement of water, whilst a different physiological process may be relatively spared – 
phagocytosis of photoreceptor outer segments. Although the genetic mechanisms 
responsible are widespread, present in all RPE cells, the clinical phenotype is likely to 
be influenced by both variations in regional metabolic activity (macular versus 
peripheral retina) and the differences between popultaions of RPE cells even within the 
macula. As RPE cells are understood to migrate centrifugally during ocular 
organogenesis, radial patterns of central RPE disease have long been identified (eg. 
dominant drusen in association with mutation of EFEMP1). Small amounts of subretinal 
deposit may therefore accumulate in a pattern that is determined primarily by clonal 
origin, with little influence of gravity. Most cases of BD however are associated with 
larger subretinal collections; under these circumstances a predisposition to radially 
distributed deposit is lost , and the greater volume of subretinal material is primarily 
influenced by gravity.  
In summary, this study describes a new retinal phenotype associated with the 
p.Ala243Val BEST1 genotype. Our study demonstrates the association of a reticular 
pattern dystrophy-like appearance with mutation in BEST1, in addition to the long 
recognised association with PRPH2, and so should be considered in the differential 
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diagnosis. This specific mutation is also associated with a later age of disease onset, and 
with greater EOG amplitudes than are usually associated with BD. These clinical 
characteristics may provide mechanistic insight, suggesting that the p.Ala243Val 
mutation acts primarily to impair ion transport and the associated movement of fluid, 
with minimal disruption to RPE phagocytosis, resulting in a later-onset maculopathy. 
Family surveys may be necessary in order to identify similarly affected individuals. 
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LEGENDS 
Figure 1. Patient 4 (p.Arg218Cys) displaying the classical changes of advanced Best 
Disease. Fundus photography reveals central macular atrophy in both eyes (A), which is 
clearly defined by fundus autofluorescence imaging (FAF), with the additional finding of 
hyperautofluorescent deposit at the most inferior aspect (B). These changes are easily 
identifiable by optical coherence tomography (OCT). 
Figure 2. Retinal appearance with mutation of p.Ala243Val BEST1 (colour fundus 
photography). Right and left eyes of Patient 1, aged 18, showing a single lesion early in 
the disease course (A). Right and left eyes of Patient 2, aged 55. Peripheral spoke-like 
components of the lesion are now visible, the most common finding in this age group of 
patients (B).  
Figure 3. Near infrared reflectance imaging (NIR-R) and corresponding optical 
coherence tomography scans for patient 3. The right eye has a predominantly 
circumferential distribution of deposit (A) whilst the left eye has additional peripheral 
spokes (B).  
Figure 4. Near infrared reflectance imaging (NIR-R) in right and left eyes of patient 6 
(A), patient 4 (B), and patient 2 (C) demonstrating the variation in phenotype associated 
with different patterns of subretinal deposit. 
Figure 5. Fundus autofluorescence (FAF) (A) and near infrared reflectance imaging 
(NIR-R) (B) for patient 4 (left hand images) and patient 6 (right hand images). Each 
modality identifies a slightly different feature of disease - NIR-R appears to be 
particularly sensitive to subtle separation of the neurosensory retinal from the RPE, and 
particularly a change in orientation of the ellipsoid zone, with increased reflectivity 
evident in regions with no or minimal change in autofluorescence (white arrows). FAF 
appears to be a more sensitive technique for detecting larger collections subretinal 
deposit (red arrows).  
 
 
